Growth inhibition and differentiation in human prostate carcinoma cells induced by the vitamin D analog 1α,24-dihydroxyvitamin D₂

Keyphrases

• Protein Level 100%
• Growth Inhibition 100%
• Growth Differentiation 100%
• Prostate Carcinoma Cells 100%
• Human Prostate 100%
• Vitamin D Analogs 100%
• LNCaP 75%
• Fold Increase 75%
• 1,25(OH)2D3 75%
• Induced Differentiation 50%
• Cell Growth 50%
• Vitamin D 50%
• Prostate-specific Antigen Level 50%
• Hypercalcemic Type 50%
• R1881 50%
• AR mRNA 50%
• Prostate Cancer 25%
• Therapeutic Modalities 25%
• Immunoblotting 25%
• Chemopreventive 25%
• Clinical Trials 25%
• Differentiation Markers 25%
• Prostate Radiotherapy 25%
• Androgens 25%
• LNCaP Cells 25%
• 1,25-Dihydroxyvitamin D3 (1,25(OH)2D3) 25%
• Cytokeratin 18 25%
• Quantitative Reverse Transcriptase PCR 25%
• ELISA Method 25%
• Cancer Intervention 25%
• Low Androgen 25%
• Real-time Quantification 25%
• DNA Level 25%
• NOR-1 25%
• Inhibit Growth 25%
• Prostate Carcinoma Cell Line 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Messenger RNA 100%
• Prostate Carcinoma 100%
• Vitamin D Analog 100%
• Prostate Cancer 66%
• Androgen 66%
• Vitamin D 66%
• Prostate Specific Antigen 66%
• Metribolone 66%
• Malignant Neoplasm 33%
• Western Blot 33%
• Clinical Trial 33%
• Enzyme-Linked Immunosorbent Assay 33%
• Calcitriol 33%
• Cytokeratin 18 33%
• Reverse Transcriptase 33%

Biochemistry, Genetics and Molecular Biology

• Growth Inhibition 100%
• LNCaP 100%
• Vitamin D Analog 100%
• Messenger RNA 75%
• Cell Growth 50%
• Vitamin D 50%
• Prostate-Specific Antigen 50%
• Quantitative Reverse Transcription Polymerase Chain Reaction 25%
• Immunoblotting 25%
• Clinical Trial 25%
• Calcitriol 25%
• Keratin 18 25%